Related Experiment Video
Updated: Jul 26, 2026
10:53
Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
Published on: July 3, 2013
[New anti-arrhythmia agents].
1Institut für Pharmakologie und Toxikologie, Technischen Universität München.
Zeitschrift Fur Kardiologie
|January 1, 1992
Summary
Class-I antiarrhythmic drugs increase mortality in post-myocardial infarction patients and should be avoided. Other antiarrhythmic agents show potential but require further clinical trials for safety and efficacy in cardiac arrhythmias.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Class-I antiarrhythmic agents (encainide, flecainide, moricizine) are used for ventricular premature depolarizations.
- Symptomatic tachyarrhythmias require careful risk-benefit assessment for class-I agents.
- New class-I drug development appears unpromising.
Purpose of the Study:
- Evaluate the efficacy and safety of antiarrhythmic agents.
- Assess the impact of antiarrhythmic drugs on mortality after myocardial infarction.
- Explore potential treatments for supraventricular and ventricular arrhythmias.
Main Methods:
- Review of clinical trials and pharmacological profiles of antiarrhythmic drugs.
- Analysis of mortality data in post-myocardial infarction patients treated with class-I agents.
- Preclinical and clinical evaluation of class-III antiarrhythmic agents.
Main Results:
- Class-I agents increase mortality in asymptomatic post-myocardial infarction patients.
- Esmolol is an effective intravenous beta-blocker for supraventricular arrhythmias.
- Class-III agents (sematilide, dofetilide) show preclinical efficacy but require clinical validation; torsades de pointes is a risk.
Conclusions:
- Avoid class-I antiarrhythmics in asymptomatic post-MI patients.
- Amiodarone and sotalol show promise for improving survival in patients at risk of sudden cardiac death.
- Further controlled trials are needed to establish the clinical value of new antiarrhythmic agents.
More Related Videos
Related Concept Videos
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:29Disturbances in Heart Rhythm
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...